Poly Medicure (NSE:POLYMED) ROCE %: 10.96% (As of Mar. 2026)


NSE:POLYMED Poly Medicure Ltd NSE:POLYMED
90 GF Score
Price ₹1,666.10
GF Value ₹2,299.45
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Poly Medicure ROCE %?

Poly Medicure NSE:POLYMED -1.26% 90 ROCE % is 10.96% as of Mar. 2026. GuruFocus rates NSE:POLYMED with a GF Score™ of 90/100 and a GF Value™ of ₹2,299.45 (Modestly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Poly Medicure's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.96%.

Poly Medicure  (NSE:POLYMED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Poly Medicure ROCE % Related Terms

Poly Medicure ROCE % Historical Data

* Premium members only.

The historical data trend for Poly Medicure's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poly Medicure ROCE % Chart

Poly Medicure Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.07 20.22 25.43 21.46 14.46

Poly Medicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.72 17.84 16.16 13.42 10.96
NSE:POLYMED
90GF Score
Poly Medicure Ltd NSE:POLYMED
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poly Medicure ROCE % Calculation

Poly Medicure's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=4457.618/( ( (31924.522 - 3701.692) + (39185.672 - 5755.224) )/ 2 )
=4457.618/( (28222.83+33430.448)/ 2 )
=4457.618/30826.639
=14.46 %

Poly Medicure's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=3665.232/( ( (0 - 0) + (39185.672 - 5755.224) )/ 1 )
=3665.232/( ( 0 + 33430.448 )/ 1 )
=3665.232/33430.448
=10.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 10.96% mean?
Poly Medicure (NSE:POLYMED) has a ROCE % of 10.96% as of Mar. 2026.
Is Poly Medicure's ROCE % too high?
Poly Medicure's current ROCE % is 10.96%. The Medical Devices & Instruments industry median ROCE % is 2.20. Poly Medicure's value of 10.96% is 398.2% above this industry median. Overall, Poly Medicure has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's ROCE % compare to ISRG and BDX?
Poly Medicure's ROCE % of 10.96% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. Poly Medicure's value of 10.96% is 398.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poly Medicure's current ROCE % of 10.96% is 398.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poly Medicure's current ROCE % is 10.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,299.45, compared to a current price of ₹1,666.10 — trading 27.5% below its estimated fair value. The current ROCE % is 10.96% and 398.2% above the Medical Devices & Instruments industry median of 2.20. Poly Medicure's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current ROCE % is 10.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?

Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued. The current stock price of ₹1,666.10 is trading 27.5% below its estimated GF Value™ of ₹2,299.45. GuruFocus considers Poly Medicure to be Modestly Undervalued.

Key valuation signals for NSE:POLYMED:

  • ROCE %: 10.96%
  • GF Value™: ₹2,299.45 vs. price of ₹1,666.10 (27.5% below fair value)
  • GF Score™: 90/100 with 6 warning signs
  • Industry Position: 398.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poly Medicure Business Description

Other Exchanges 531768:India
Address Okhla Industrial Estate, 232-B, 3rd Floor, Phase III, New Delhi, IND, 110020
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
90GF Score

Get the complete analysis for NSE:POLYMED

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,666.10
Price
₹2,299.45
GF Value